A Phase 2 Study of Alisertib (MLN8237) in Recurrent or Persistent Uterine Leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group Study 0231D
Gynecologic Oncology - United States
doi 10.1016/j.ygyno.2016.10.036
Full Text
Open PDFAbstract
Available in full text
Date
January 1, 2017
Authors
Publisher
Elsevier BV